CAS NO: | 2170606-74-1 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | DB2313 is a potent transcription factorPU.1inhibitor with anapoptosisof 14 nM. DB2313 disrupts the interaction ofPU.1with target gene promoters. DB2313 inducesapoptosisof acute myeloid leukemia (AML) cells, and has anticancer effects[1]. | ||||||||||||||||
IC50& Target | IC50: 14 nM (PU.1)[1] | ||||||||||||||||
体外研究 (In Vitro) | DB2313 treatment leads to a profound decrease in the growth of PU.1 URE–/–acute myeloid leukemia (AML) cells (IC50of 7.1 μM), while showing little effect on normal hematopoietic cells at similar concentrations. DB2313 treatment leads to a 3.5-fold increase in apoptotic cells in murine PU.1 URE–/–AML cells. DB2313 also leads to a significant decrease in clonogenicity in the second and third rounds of plating and a complete disruption of clonogenic capacity in the fourth and higher rounds of plating[1]. | ||||||||||||||||
体内研究 (In Vivo) | DB2313 (17 mg/kg; i.p.; three times per week; for 3 weeks) treatment decreases leukemia progression and results in increased survival in mice[1].
| ||||||||||||||||
分子量 | 708.83 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C42H41FN8O2 | ||||||||||||||||
CAS 号 | 2170606-74-1 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 3.7 mg/mL(5.22 mM;ultrasonic and warming and heat to 70℃) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*以上所有助溶剂都可在本网站选购。 |